(Head office: Sumida-ku, Tokyo; Representative Director: Yoshinobu Osaka) has invested in LYMPHOGENiX Limited (Head office: London, UK; Directors: Takahiro Iwamiya and Masayuki Matsunaga; hereinafter "LYMPHOGENiX").

LYMPHOGENiX is a bio-venture company with the vision of "supporting the continuity of life through lymphatic regeneration technology" and is developing solutions to treat infertility in humans and livestock animals by fundamentally improving the endometrial environment with its core technologies of cell activation technology and extracellular factor preparations (culture supernatant fluid) that induce lymphatic regeneration, toward social implementation of regenerative medicine and fertility medicine. The company is a bio-venture company that develops solutions to treat infertility in humans and livestock animals without relying on hormones by fundamentally improving the endometrial environment.

The company is currently engaged in the research and development of fertility products for livestock animals and human infertility treatment products for endometrial fibrosis. In the future, we plan to focus on building a business foundation by acquiring non-clinical data for clinical trials and developing manufacturing infrastructure.

LYMPHOGENiX's lymphatic vessel regeneration technology has the potential to be applied not only to infertility treatment but also to a wide range of diseases such as heart failure, pulmonary fibrosis, skin aging, obesity, and Alzheimer's disease.

LYMPHOGENiX Press Release
https://prtimes.jp/main/html/rd/p/000000001.000162999.html

Contact]
Company name LYMPHOGENiX Limited 
Location 71-75 Shelton Street, London WC2H 9JQ, United Kingdom
Representative Director Takahiro Iwamiya, Masayuki Matsunaga
U R L https://www.lymphogenix.com
Contact [email protected]

Company name GLOKA LINK Inc.
Location Center of Garage, 1-16-3 Yokogawa, Sumida-ku, Tokyo 130-0003, Japan
Representative Yoshinobu Osaka, Representative Director
U R L https://glocalink.com
Contact https://glocalink.com/contact